Quantcast
Last updated on April 18, 2014 at 16:41 EDT

Latest Low-Grade Serous Ovarian Cancer Stories

2013-07-02 08:26:31

BOULDER, Colo., July 2, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer (LGSOC). (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), is a multinational, randomized Phase 3 trial and will evaluate MEK162 against physician's choice of...

2013-05-15 08:30:29

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4, 2013 in Chicago, Illinois. Both MEK inhibitors are expected to advance into Phase 3 trials in 2013: Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma and Array...

2013-05-06 16:27:04

-Targets difficult-to-treat patient population with few remaining options - BOULDER, Colo., May 6, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer (LGSOC) during the summer of 2013. The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy...